Superworth

Enanta Pharmaceuticals profit margin ENTA

Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.

Net margin, 12 months
−96.9%
Operating margin, 12 months
−90.0%
Peer median
11.6%

Over the twelve months to Jun 30, 2026, Enanta Pharmaceuticals kept −96.9% of its revenue as net profit, with an operating margin of −90.0%.

Five years earlier its net margin was −86.2%.

The median for 10 large drugmakers of a similar size is 11.6%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY2024n/an/a
FY2023n/an/a
FY2022n/an/a
FY2021−81.4%n/a
FY2020−29.5%−34.0%
FY201922.6%17.9%
FY201834.8%42.7%
FY201717.2%23.9%
FY201624.5%34.9%
FY201549.1%77.2%
FY201472.1%39.8%
FY201330.0%28.2%
FY201251.3%51.0%

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q3 FY26−96.9%n/a−90.0%
Q2 FY26−89.6%n/a−87.2%
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Enanta Pharmaceuticals' size, closest first, today.

CompanyProfit margin
ENTAEnanta Pharmaceuticals−96.9%
ARVNArvinas2.9%
NATRNatures Sunshine Products3.7%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
COLLCollegium Pharmaceutical5.9%
ABUSArbutus Biopharma84.2%
AMPHAmphastar Pharmaceuticals10.8%
OMEROmerosn/m
Peer median11.6%

Where Enanta Pharmaceuticals ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Enanta Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.